Our Blog & Resources
Unlock a goldmine of cutting-edge knowledge and resources on our blog, where we delve into the forefront of precision medicine, offering expert perspectives, actionable insights, and game-changing discoveries to empower your journey in shaping the future of healthcare.
Advanced filters :
MGI and OncoDNA join forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) OncoDEEP® Kit in clinical practice
Gosselies – Belgium, October 29, 2024 MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced...
The NHS South East Genomic Medicine Service transitions to the OncoDEEP Kit a Solid Tumour Panel that can transform oncology patients’ lives as a result of timely comprehensive genomic testing.
The NHS South East Genomic Medicine Service serves approximately 15.4% of the population of England and seeks to improve patient outcomes through care pathway development enabling timely and equitable access to genomic testing and genomically...
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.
Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory. Gosselies, Belgium and Paris,...
Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine
Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...
OncoDNA laboratory has received the CAP accreditation
Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...
OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, Germany
OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment, today has announced the implementation of OncoDEEP® Kit in clinical routine by the Institute of Pathology at the Klinikum Region Hannover...
OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancer
OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today has announced its support to the extension of the AURORA program, which aims to...
OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands
OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands The ETZ (Elisabeth-TweeSteden Hospital) is a leading hospital offering multiple clinical specialties including oncology and trauma across...
OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house
OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house. Gosselies, Belgium, October 20th, 2023 – OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment,...
C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe
OncoDNA’s lab in France is the first in the EU to enable access to the C2inform test for clinical decision-making Gosselies — (October 19, 2023) — OncoDNA, a genomic and theranostic company specializing in precision...
OncoDNA announces the closing of a round C financing of 6,5 M€
OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 M€, entirely subscribed by...
Collaboration between OncoDNA and Eli Lilly Italia to broaden access to biomarker testing for thyroid cancer patients
Biomarker testing to help clinicians in Italy to make precision medicine innovation accessible based on the identification of molecular alterations for thyroid cancer patients OncoDNA, a company specializing in precision medicine for the treatment of...
Berkshire and Surrey Pathology Services & OncoDNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK
Dr Cheng Boon, oncologist in the private sector and the NHS as well as acting as OncoDNA UK medial director commented “In my view, this is an important first step in a collaboration that will...
OncoDNA announces the operational launch of its OncoDEEP® Kit for comprehensive genomic profiling of solid tumors
A unique workflow solution integrating a pan-cancer next-generation sequencing (ngs) panel powered by a bioinformatics software suite for customizable biological and clinical interpretation. OncoDNA, a genomic and theranostic company specializing in precision medicine for the...
OncoDNA and Synlab partner to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany
Synlab laboratories to perform OncoDEEP® biomarker test to help doctors decide on the most effective treatment for their cancer patients. OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer...
OncoDNA launches OncoDEEP® Kit for comprehensive biomarker testing of solid tumors
Unique workflow solution integrating a comprensive pan-cancer NGS panel powered by Twist Bioscience and a bioinformatics software suite. OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic...
C2i Genomics partners with OncoDNA to bring AI-powered liquid biopsy for cancer diagnostics across Europe
This partnership marks C2i’s launch into the EU and a first-of-its kind interventional clinical trial led by the Gustave Roussy Institute in France C2i Genomics, a cancer intelligence company, today announced expansion into Europe through...
OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology
The Appolo study will assess the impact of biomarker testing on access to precision medicines and on posttreatment surveillance for cancer patients across the sounth of France. OncoDNA, a genomic and theranostic company specializing in...
OncoDNA provides strategic support in Radiomics’ prospective clinical trial SALMON
The two belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using ai technology. Radiomics and OncoDNA are pleased to announce that they have entered...
OncoDNA teams up with SOPHiA GENETICS to enable laboratories to establish data-driven medicine as a standard of care
OncoDNA’s OncoKDM® clinical interpretation platform to be optimized for the use with Sophia DDM™ to match tumor genomic profiles with targeted therapies. OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment...
New partnership to advance identification of best treatments for cancer patients
A new partnership between Rutherford Health PLC, a healthcare group committed to providing innovative cancer care, and OncoDNA, a genomic and theranostic company specialising in precision medicine, has been announced today. The partnership will provide...
Collaboration between Bayer Saudi Arabia LLC, OncoDNA and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia
NTRK biomarker testing to identify patients most likely to benefit from treatment with targeted TRK inhibitors therapies. OncoDNA, Tamkin Al-Seha Medical and Bayer Saudi Arabia announced today a new partnership to broaden access to Neurotrophic...
Institut Jules Bordet collaborates with OncoDNA to explore biology of brain metastases using personalized liquid biopsy from cerebrospinal fluid
The brainstorm study, sponsored by Institut Jules Bordet and the Oncodistinct network, will investigate CSF samples in the hope of identifying promising prognostic, predictive, monitoring biomarkers of brain metastases. OncoDNA, a theranostic and genomic company...
OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers
The OncoFOLLOW™ tests will help monitor disease progression in patients under treatment within the scandare study. OncoDNA, a theranostic and genomic company specializing in precision medicine, announced the launch of a research project in collaboration...
Fighting cancer with personalized vaccines: OncoDNA and myNEO join forces to unlock the power of mRNA therapeutics
The companies will combine their advanced technologies to provide an individualized vaccine design for patients with no treatment options. OncoDNA and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce today...
OncoDNA supports BSMO project to advance precision medicine for late stage cancer patients across Belgium
Nation-wide study will measure the impact of comprehensive genomic profiling on access to, and uptake of, personalised medicines and on clinical outcomes for patients across Belgium GOSSELIES, FEBRUARY 4, 2021 – Today, the Belgian Society of...
OncoDNA appoints Dr Bernard Courtieu as Chief Executive Officer
Bernard Courtieu, previously CEO of Integragen, is named CEO of OncoDNA. Jean-Pol Detiffe, founder of OncoDNA, is named chief strategic & innovation officer, specifically in charge of strategic alliances and business development. JANUARY 25, 2021...
OncoDNA announces expansion of its services into the United States
The theranostic and genomic company signs subcontract service agreement with HalioDx’s CLIA-certified laboratory in Richmond, Virginia. OncoDNA, a theranostic and genomic company specializing in precision oncology, has announced today that it has signed a subcontract...
OncoDNA wins the Biotech Award of Deloitte’s 2020 Technology Fast50 competition
Gosselies, 27 november 2020 – Already celebrated by Deloitte’s Technology Fast50 in 2015 and 2018, OncoDNA is thrilled to announce that it has received this year’s Award in the biotechnology and pharmaceutical category. Deloitte’s Technology...
New molecular diagnostic innovation partnership to facilitate patient access to personalised cancer care across the UK
OncoDNA, the healthcare technology company making precision medicine in oncology a reality, has announced the launch of the Molecular Diagnostic Innovation Partnership (MDIP) during a virtual panel discussion co-organised with Rutherford Diagnostics hosting experts from Macmillan Cancer Support, Aviva and...
Successful friendly takeover bid initiated by OncoDNA on IntegraGen’shares
OncoDNA, a private, oncology-focused healthcare technology company, following the announcement of the final results made by the French financial markets authority (the “AMF”), is very pleased to announce the success of its friendly takeover bid...
OncoDNA has been nominated for the Deloitte’s 2020 Technology Fast 50
OncoDNA has been nominated for 2020 Deloitte’s Technology Fast 50 competition for technology companies headquartered in Belgium and founded in Belgium. The Fast 50 award will be given to the country’s fastest-growing technology company, based...
